Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the bladder

WOS: 000474443200007PubMed ID: 30183610Objective: The aim of this study was to evaluate the prognostic significance of tumor budding in muscle invasive urothelial carcinoma of bladder (MIBC). Material and methods: A total of 60 patients who underwent radical cystectomy and cystoprostatectomy for MIBC were included in the study. The correlations between tumor budding, and tumor necrosis, lymphovascular invasion (LVI), perineural invasion (PNI) and histopathological data with distant metastasis were evaluated. The correlation between progression free (PFS) and overall survival (OS) rates and the presence, and grade of tumor budding was investigated. Results: A statistically significant correlation was not seen between tumor budding, necrosis, LVI, and PNI. There was a strong correlation between distant organ metastasis, and presence of tumor necrosis. There was no statistically significant correlation between PFS, OS and tumor budding. A statistically significant relationship was observed between OS and tumor stage, lymph node metastasis, and distant organ metastasis. Conclusion: In our study, statistically significant effect of tumor budding on survival rates in MIBCs was not observed. Also, no significant correlation was observed between tumor budding and tumor necrosis, LVI, and PNI

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma

Background: The expression levels of Programmed death ligand-1 (PD-L1), epidermal growth factor receptor (EGFR), anaplastic lymphoma tyrosine kinase gene (ALK), and proto-oncogene tyrosine-protein kinase 1 ROS (ROS1) are important for targeted treatment selection in advanced lung cancer. Most patients with lung cancer are diagnosed at an advanced stage and have no chance of surgery. For this reason, the accuracy and reliability of cytology samples for detecting those markers is important in patients whose histological sampling cannot be performed. Aims: To test the compatibility of histological and cytological sample analysis results of EGFR, ALK, ROS1 and PDL-1 in patients with NSCLC and to determine the adequacy of cytological analysis for PD-L1 expression. Study Design: Retrospective cross-sectional study. Methods: The results of 231 patients whose PD-L1 was studied in 2018 were analyzed retrospectively. We excluded 11 inappropriate samples. A total of 220 samples were distributed as follows; 66 (30.0%) cytology specimens, 64 (29.1%) small histology biopsies, and 90 (40.9%) surgical biopsies. EGFR, ALK, ROS1 and PD-L1 analysis were performed in 139, 134, 116, and 220 patients, respectively. Samples containing >400 cells were considered suitable for molecular cytological study. Results: A total of 154 (70.0%) histological (surgical biopsy) and 66 (30.0%) cytology samples were analyzed. There was no statistically significant difference between histological and cytological samples in terms of cellular adequacy for all molecular markers [EGFR: 93.7% and 90.9% (P=.556), ALK: 97.8% and 95.3% (P=.436), ROS1: 89.9% vs. 91.9% (P=.729), PD-L1: 95.5% vs. 92.4% (P=.364)]. There was no statistically significant difference in the expression positivity rates of all biomarkers between histological and cytological samples [EGFR: 9.0% vs. 2.5% (P=.018), ALK: 7.9% vs. 9.8% (P=.719), ROS1 : 1.4% vs. 2.9% (P=.591), PD-L1: 54.4% vs. 41.0% (P=.078)]. Conclusion: The cellular adequacy of cytology specimens for molecular testing in patients with NSCLC is satisfactory. This study shows that EGFR, ALK, ROS-1 and PDL-1 expression rates in cytological samples are not statistically different from histological samples

Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer

Background/Aims: Human epididymal secretory protein 4 (HE4) is originally described as an epididymis-specific protein but more recently suggested to be a putative serum tumor marker for some tumors, including breast carcinomas. In this study, we aimed to investigate the interactions between HE4 expression and molecular subtypes of breast carcinomas. Methods: HE4 expressions were studied in 242 formalin-fixed, paraffin-embedded breast carcinoma specimens and their association with different pathological and clinical parameters was evaluated. Results: Immunohistochemical (IHC) staining for HE4 was negative in 3 (1.2%) cases, weakly positive (1+) in 7 (2.9%) cases, moderately positive (2+) in 58 (24.0%) cases, and strongly positive (3+) in 174 (71.9%) cases. A correlation between IHC HE4 staining grade and molecular groups was detected (P = 0.005). Furthermore, it was found that HE4 expression was strongly associated with histological tumor grade, c-erbB2 expression, and positive fluorescence in situ hybridization test results that detect human epidermal growth factor receptor 2 (HER2)/neu amplification (P = 0.022, P = 0.014, and P = 0.011). Conclusion: This study showed that HE4 expression is associated with HER2/neu amplification in breast cancers. These results may be commented as HE4 expression rises in patients with HER2/neu amplification. As is known, HER2/neu amplification is a poor diagnostic factor in breast cancer and HE4 expression is possibly associated with poor prognosis

Documentation of our neuroblastoma cases (49 cases, retrospective study)

Objective: Neuroblastoma (NB) is the most common extracranial solid cancer in childhood and the most common cancer in infancy. Nearly half of neuroblastoma cases occur in children younger than two years. It is a neuroendocrine tumor, arising from neural crest. It most frequently originates from one of the adrenal glands, but can also develop in neural tissues in the neck, chest, abdomen, or pelvis. In this study, neuroblastoma cases were reviewed and classified occording to the Shimada classification

Expression of Stromal Caveolin-1 May Be a Predictor for Aggressive Behaviour of Breast Cancer

Caveolin-1 (Cav-1) is well known as a principal scaffolding protein of caveolae which are specialized plasma membrane structures. The role of Cav-1 in tumorigenesis of breast cancers is relatively less studied. The aim of the present study is to describe the biological roles of Cav-1 in breast cancers considering its contrasting dual functions as an oncogene and as a tumor suppressor. This study included 71 females with breast cancer who had been histopathologically diagnosed in Private Gunes Pathology Laboratory between the years 2007, and 2012. The mean age is 52.48 +/- 12.8 years. Patients were followed up for a mean period of 47.97 +/- 20.48 months. We didn't determine Cav-1 positive tumor cells. In 36 cases (50.7%), there were stromal expressions of Cav-1. In the statistical analysis, there was a statistically significant correlation between Cav-1 expression and ER (p = 0.033), metastasis (p = 0.005), lymphatic invasion (p = 0.000), nodal metastasis (p = 0,003), perinodal invasion (p = 0.003), metastasis (p = 0.005) and survival (p = 0.009). We found that Cav-1 expression is associated with tumor size, histological grade, lymph node involvement. Accordingly, we have suggested that Cav-1 may be a predictive biomarker for breast cancer

Comparison of Eosinophilic and Non-eosinophilic Cases with Chronic Obstructive Pulmonary Disease (COPD) in terms of Clinical Arrival, Exacerbations, Quality of Life and Response to Treatment: A Prospective Study

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAINWOS: 000507372403105[No abstract available]European Respiratory So